R01: Preclinical drug repurposing & combination therapies for Alzheimer’s (clinical trials not allowed)
This R01 funds rigorous preclinical proof-of-concept testing of drug candidates and drug combinations identified by data-driven/translational bioinformatics for treatment or prevention of Alzheimer’s disease and related dementias. Projects should use mouse or cell-based models (e.g., iPSCs, organoids), follow NIH rigor and ARRIVE guidelines, prioritize candidates (including failed Phase II/III…
Drug repurposing has several advantages over the development of new drugs including, shorter development times, lesser cost of development, and higher success rates. This has been done successfully for several disease conditions, however, despite multiple attempts at drug repurposing for Alzheim…
Funding Source
Awards & funding
Eligibility
- Foreign/Non-domestic eligibility: Non-domestic (non-U.S.) entities (foreign organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. organizations are eligible. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Required registr…
Dates
Supporting links
Secure Grant Funding 10x Faster
Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.
Already have an account? Sign In
Trusted by 500+ Happy Customers